AbbVie (ABBV) Change in Accured Expenses (2012 - 2026)

AbbVie has disclosed Change in Accured Expenses across 15 years of filings, most recently posting -$1.6 billion for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 129.02% year-over-year to -$1.6 billion; the TTM figure through Mar 2026 stood at $53.0 million (up 106.02% YoY), while the FY2025 annual figure was $951.0 million, up 437.29% from the prior year.
• Change in Accured Expenses declined to -$1.6 billion in Q1 2026, from -$598.0 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for ABBV reached as high as $2.5 billion in Q3 2023 and fell as low as -$1.7 billion in Q2 2024.
• The 5-year median for Change in Accured Expenses is $267.0 million (2024), against an average of $302.5 million.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 363.89% — and 2023, when it soared 928.42%.
• A 5-year view of Change in Accured Expenses shows it stood at $1.3 billion in 2022, then sank by 85.99% to $179.0 million in 2023, then soared by 596.65% to $1.2 billion in 2024, then tumbled by 147.96% to -$598.0 million in 2025, then tumbled by 166.56% to -$1.6 billion in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$1.6 billion, -$598.0 million, and $1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.